Clinical Trial Update: LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations [Phase 2]

View source ↗

Summary

Phase II single-arm trial evaluating afatinib (BIBW 2992) in non-small cell lung cancer with EGFR activating mutations; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2013-10-14